CIMdata PLM Industry Summary Online Archive

5 October 2004

Implementation Investments

Major U.S.-Based Pharmaceutical Company Selects Framework Technologies To Manage Capital Projects On All Worldwide Facilities

Framework Technologies announced that a leading U.S.-based pharmaceutical company has selected its ActiveAECT solution to manage its entire global facilities portfolio including new construction, expansion and renovation projects.   The company's facilities that comprise development, manufacturing, distribution and administration functions are found in 35 major locations, with seventy percent of those located outside of the United States. This deal represents the latest in a series of major wins for Framework's AEC solution, including Princeton University Facilities Department, Iowa State University, University of Southern California and Best Buy.

Framework's ActiveAEC addresses the challenges associated with facilities design and construction by allowing project teams to leverage project information from heterogeneous IT systems and to optimize cross-project communication among internal employees, contractors, sub-contractors, consultants, and suppliers eliminating miscommunication and reducing project schedule delays. ActiveAEC ensures team member accountability by providing access to dynamically changing project information instantly and securely. Company executives will now have insight into the entire facilities project and asset portfolio and be able to make timely and accurate decisions.

"To have one of the largest and pre-eminent pharmaceutical companies in the world using ActiveAEC for their global facilities improvement plans is a major validation of our solution," said Donald Tomkinson, CEO of Framework Technologies.   "Our solution will help everyone, senior executives, project managers, and contractors to understand what is going on at all times and help them meet or exceed their aggressive capital improvement goals."

Pharmaceutical manufacturing facilities require significant ongoing capital investment for both maintenance and to comply with increasing regulatory requirements.   In addition to these challenges, the company is undergoing rapid strategic changes designed to focus on the research and development of new biologic drugs.   Biologics manufacturing involves more complex processes than those of traditional pharmaceutical operations and as a result, the company envisions significant capital investment at a number of facilities around the world.

 

Become a member of the CIMdata PLM Community to receive your daily PLM news and much more.

Tell us what you think of the CIMdata Newsletter. Send your feedback.

CIMdata is committed to your privacy. Your personal information will never be sold or shared outside of CIMdata without your express permission.

Subscribe